Table 6.

Multivariate analysis of overall survival for all patients combined, using new cytogenetic risk groups

Variable	Hazard ratio	p
Prior therapy	0.9	0.4
Cytogenetics
Standard-risk (reference)	1.0
Favorable	0.3	<0.0001
Adverse	2.4	<0.0001
Not available	1.3	0.2
Age	1.03	<0.0001
Disease/Stage
AML in CR1 (reference)	1.0
CR≥1	2.7	<0.0001
Active disease	2.7	<0.0001
RA/RARS/RCMD	0.9	0.6
RAEB	1.3	0.3
mAML in CR1	0.9	0.3
Match
MRD (reference)	1.0
MUD	1.3	0.038
Mismatched	2.1	0.0002
GVHD prophylaxis
CnI +/− Mtx* (reference)	1.0
CnI + Rapa +/− Mtx	0.7	0.036
TCD	1.0	0.8

Conditioning regimen (myeloablative versus reduced-intensity), graft source (bone marrow versus peripheral blood versus cord blood), CMV serostatus of donor and recipient (positive versus negative or unknown), female-to-male transplant, and year of transplant (in 10-year blocks) were not significant in this analysis.

^*+/− steroids

Abbreviations are explained in Table 1.